IMV Issues Update On Its COVID-19 Vaccine Program - Quick Facts

(RTTNews) - IMV Inc. (IMV) has received notification from the Government of Canada indicating that the company's DPX-COVID-19 vaccine candidate had met the required scientific and technical thresholds for funding. The National Research Council of Canada Industrial Research Assistance Program is providing advisory services and up to $5.4 million in funding to support the continuation of clinical trials.

IMV's vaccine candidate, DPX-COVID-19, is a synthetic, targeted vaccine intended for the prevention of COVID-19 infection. The company has decided to combine its original phase 1 and 2 studies into a single trial with the potential to accelerate the clinical development. The phase 1/2 trial is anticipated to be initiated before the end of 2020. The preclinical studies have been ongoing since mid-August.

Also, IMV has entered a collaboration with a global manufacturing partner. The company said this collaboration has the potential to bring two additional production sites in India and Europe.